Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan

Rosiglitazone Treatment of Type 2 Diabetic db/db Mice Attenuates Urinary Albumin and Angiotensin Converting Enzyme 2 Excretion

(2013) Harshita Chodavarapu et al.   PLoS One

T/L-type calcium channel blocker reduces the composite ranking of relative risk according to new KDIGO guidelines in patients with chronic kidney disease

(2013) Masanori Abe et al.   BMC Nephrology

High urinary ACE2 concentrations are associated with severity of glucose intolerance and microalbuminuria

(2012) Se Eun Park et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease

(2012) Masanori Abe et al.   HEART AND VESSELS

Possible Involvement of Angiotensin-Converting Enzyme 2 and Mas Activation in Inhibitory Effects of Angiotensin II Type 1 Receptor Blockade on Vascular Remodeling

(2012) Masaru Iwai et al.   HYPERTENSION

Enhanced Angiotensin II-Induced Cardiac and Aortic Remodeling in ACE2 Knockout Mice

(2012) Mahmoud S. Alghamri et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice

(2012) Renisha Nadarajah et al.   KIDNEY INTERNATIONAL

Increased Urinary Angiotensin-Converting Enzyme 2 in Renal Transplant Patients with Diabetes

(2012) Fengxia Xiao et al.   PLoS One

Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria

(2011) Masanori Abe et al.   HYPERTENSION RESEARCH

Effects of Lipid-Lowering Therapy with Rosuvastatin on Kidney Function and Oxidative Stress in Patients with Diabetic Nephropathy

(2011) Masanori Abe et al.   Journal of Atherosclerosis and Thrombosis

Unknown

(2011) Chun Liu et al.   MOLECULAR MEDICINE

ACE2 and Ang-(1-7) Confer Protection Against Development of Diabetic Retinopathy

(2011) Amrisha Verma et al.   MOLECULAR THERAPY

Urinary angiotensin-converting enzyme 2 in patients with CKD

(2011) SONOO MIZUIRI et al.   NEPHROLOGY

Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction

(2010) JiuChang Zhong et al.   CIRCULATION

Revised Equations for Estimated GFR From Serum Creatinine in Japan

(2009) Seiichi Matsuo et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Human Recombinant ACE2 Reduces the Progression of Diabetic Nephropathy

(2009) G. Y. Oudit et al.   DIABETES

Cardiovascular and autonomic phenotype ofdb/dbdiabetic mice

(2009) Danielle Senador et al.   EXPERIMENTAL PHYSIOLOGY

Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2

(2009) Jan Wysocki et al.   HYPERTENSION

The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension

(2009)   HYPERTENSION RESEARCH

Molecule-specific Effects of Angiotensin II-Receptor Blockers Independent of the Renin-Angiotensin System

(2008) T. W. Kurtz et al.   AMERICAN JOURNAL OF HYPERTENSION

Expression of ACE and ACE2 in Individuals With Diabetic Kidney Disease and Healthy Controls

(2008) Sonoo Mizuiri et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease

(2008) Heather N. Reich et al.   KIDNEY INTERNATIONAL